BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26341038)

  • 1. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.
    Kwon YS; Han CS; Yu JW; Kim S; Modi P; Davis R; Park JH; Lee P; Ha YS; Kim WJ; Kim IY
    Clin Genitourin Cancer; 2016 Feb; 14(1):e1-8. PubMed ID: 26341038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy.
    Zhang GM; Zhu Y; Ma XC; Qin XJ; Wan FN; Dai B; Sun LJ; Ye DW
    Medicine (Baltimore); 2015 Oct; 94(41):e1473. PubMed ID: 26469891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy.
    Lee H; Jeong SJ; Hong SK; Byun SS; Lee SE; Oh JJ
    World J Urol; 2016 Jun; 34(6):821-7. PubMed ID: 26449784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients.
    Ferro M; Musi G; Serino A; Cozzi G; Mistretta FA; Costa B; Bianchi R; Cordima G; Luzzago S; Di Trapani E; Tagliabue E; Vartolomei MD; Terracciano D; Cassatella MC; Salvatici M; Conti A; Sandri MT; Cioffi A; Turetti M; Catellani M; Bottero D; Matei DV; Mirone V; de Cobelli O
    Urol Int; 2019; 102(1):43-50. PubMed ID: 30408799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
    Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer.
    Jang WS; Cho KS; Kim KH; Yoon CY; Kang YJ; Lee JY; Ham WS; Rha KH; Hong SJ; Choi YD
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):298-304. PubMed ID: 27349499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.
    Bakavičius A; Drevinskaitė M; Daniūnaitė K; Barisienė M; Jarmalaitė S; Jankevičius F
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32033148
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance.
    Gokce MI; Tangal S; Hamidi N; Suer E; Ibis MA; Beduk Y
    Can Urol Assoc J; 2016; 10(11-12):E383-E387. PubMed ID: 28096923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer.
    Kang HW; Jung HD; Lee JY; Kwon JK; Jeh SU; Cho KS; Ham WS; Choi YD
    Asian J Androl; 2016; 18(3):480-4. PubMed ID: 26178393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.
    Sooriakumaran P; Haendler L; Nyberg T; Gronberg H; Nilsson A; Carlsson S; Hosseini A; Adding C; Jonsson M; Ploumidis A; Egevad L; Steineck G; Wiklund P
    Eur Urol; 2012 Nov; 62(5):768-74. PubMed ID: 22633365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
    Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
    Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic utility of neutrophil-to-lymphocyte and platelets-to-lymphocyte ratio in predicting biochemical recurrence post robotic prostatectomy.
    Zanaty M; Ajib K; Alnazari M; El Rassy E; Aoun F; Zorn KC; El-Hakim A
    Biomark Med; 2018 Aug; 12(8):841-848. PubMed ID: 30019909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy.
    Kawahara T; Fukui S; Sakamaki K; Ito Y; Ito H; Kobayashi N; Izumi K; Yokomizo Y; Miyoshi Y; Makiyama K; Nakaigawa N; Yamanaka T; Yao M; Miyamoto H; Uemura H
    Oncotarget; 2015 Oct; 6(31):32169-76. PubMed ID: 26359354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence.
    Knipper S; Sadat-Khonsari M; Boehm K; Mandel P; Budäus L; Steuber T; Maurer T; Heinzer H; Schwarz R; Sauter G; Tilki D; Huland H; Graefen M
    Clin Genitourin Cancer; 2020 Apr; 18(2):e112-e121. PubMed ID: 31648965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy.
    Özsoy M; Moschini M; Fajkovic H; Soria F; Seitz C; Klatte T; Gust K; Briganti A; Karakiewicz PI; Roupret M; Kramer G; Shariat SF
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):100-105. PubMed ID: 29230007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
    Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
    Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.